CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China

Yanfen Feng, Huilan Rao, Yiyan Lei, Yuhua Huang, Fang Wang, Yu Zhang, Shaoyan Xi, Qiuliang Wu, Jianyong Shao, Yanfen Feng, Huilan Rao, Yiyan Lei, Yuhua Huang, Fang Wang, Yu Zhang, Shaoyan Xi, Qiuliang Wu, Jianyong Shao

Abstract

Background: Mature T-cell and natural killer (NK)-cell lymphomas compose a heterogeneous group of non-Hodgkin lymphomas, and extranodal NK/T-cell lymphoma, nasal type (ENKTL) is an aggressive subtype with sporadic CD30 expression. However, the significance of CD30 expression in ENKTL is controversial. We aimed to classify a large cohort of patients with mature T-cell and NK-cell lymphomas according to the 2016 World Health Organization (WHO) classification guidelines and to study the association between CD30 expression and prognosis of patients with ENKTL.

Methods: We selected consecutive patients with mature T-cell and NK-cell lymphomas who attended our institution between September 1, 2009 and August 31, 2013. We classified the lymphomas according to the 2016 revision of the WHO classification of lymphoid neoplasms, analyzed the associations between CD30 expression and clinicopathologic features of ENKTL patients, and evaluated the prognostic implications of CD30 expression.

Results: We identified 622 consecutive patients with mature T-cell and NK-cell lymphomas, including 317 (51.0%) patients with ENKTL. In addition, CD30 expression was detected in 43 (47.3%) of a subset of 91 patients with ENKTL. No clinicopathologic features were associated with CD30 expression, and CD30 positivity showed no prognostic significance in patients with ENKTL.

Conclusions: ENKTL is the most common type of mature T-cell and NK-cell lymphoma diagnosed at our institution. CD30 is frequently expressed in ENKTL and represents a therapeutic target; however, it may not be a prognostic marker.

Keywords: CD30; Epstein-Barr virus; Lymphoma; Natural killer cell; T cell.

Figures

Fig. 1
Fig. 1
Morphology of different subtypes of T-cell and natural killer (NK)-cell lymphoma (hematoxylin–eosin staining, ×400). a Extranodal NK/T cell lymphoma, nasal type (ENKTL) shows medium-sized tumor cells with apoptotic bodies. b Angioimmunoblastic T-cell lymphoma (AITL) shows proliferation of high endothelial venules, polymorphic infiltrating cells, and cells with clear-to-pale cytoplasm. c Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) shows medium- to large-sized polymorphic tumor cells with high mitotic figure rates. d Anaplastic lymphoma kinase (ALK)-positive, anaplastic large-cell lymphoma (ALCL) shows cells with horseshoe or kidney-shaped nuclei and inflammation
Fig. 2
Fig. 2
Immunohistochemical staining (IHC) and in situ hybridization (ISH) staining of ENKTL. a Tumor cells show strong membranous and cytoplasmic expression of CD56 (IHC, ×200). b Tumor cells show strong nuclear expression of Epstein-Barr virus (EBV)-encoded small RNA (ISH, ×200). c Tumor cells show strong diffuse membranous and Golgi zone expression of CD30 (IHC, ×200)
Fig. 3
Fig. 3
Survival curves of 91 patients with ENKTL as stratified by CD30 expression. a Overall survival; b Progression-free survival
Fig. 4
Fig. 4
Survival curves of 81 patients with ENKTL as stratified by plasma EBV-DNA status. a Overall survival; b Progression-free survival

References

    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H. WHO Classification of tumors of hematopoietic and lymphoid tissues. 4. Lyon: IARC Press; 2008.
    1. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130. doi: 10.1200/JCO.2008.16.4558.
    1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi: 10.1182/blood-2016-01-643569.
    1. Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014;25(11):2211–2217. doi: 10.1093/annonc/mdu443.
    1. Niu SQ, Yang Y, Li YY, Wen G, Wang L, Li ZM, et al. Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma. Chin J Cancer. 2016;35:34. doi: 10.1186/s40880-016-0096-0.
    1. Chen R, Chen B. Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma. Drug Des Devel Ther. 2015;2015(9):1729–1733. doi: 10.2147/DDDT.S82007.
    1. Schirrmann T, Steinwand M, Wezler X, Ten Haaf A, Tur MK, Barth S. CD30 as a therapeutic target for lymphoma. BioDrugs. 2014;28(2):181–209. doi: 10.1007/s40259-013-0068-8.
    1. Feng Y, Fu J, Yan S, Ling Y, Huang Y, Cai M, et al. Analysis of mature T-cell and NK-cell lymphoma with CD30 expression based on latest WHO classification. Zhonghua Bing Li Xue Za Zhi. 2014;43(8):508–511.
    1. Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013;121(14):2715–2724. doi: 10.1182/blood-2012-10-461848.
    1. Ren YL, Nong L, Zhang S, Zhao J, Zhang XM, Li T. Analysis of 142 northern Chinese patients with peripheral T/NK-Cell lymphomas: subtype distribution, clinicopathologic features, and prognosis. Am J Clin Pathol. 2012;138(3):435–447. doi: 10.1309/AJCPWKJ3GPFRT7GA.
    1. Niitsu N, Okamoto M, Nakamine H, Aoki S, Motomura S, Hirano M. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Hematol Oncol. 2008;26(3):152–158. doi: 10.1002/hon.853.
    1. Li Z, Xia Y, Feng LN, Chen JR, Li HM, Cui J, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncol. 2016;17(9):1240–1247. doi: 10.1016/S1470-2045(16)30148-6.
    1. Wright CW, Rumble JM, Duckett CS. CD30 activates both the canonical and alternative NF-κB pathways in anaplastic large cell lymphoma cells. J Biol Chem. 2007;282(14):10252–10262. doi: 10.1074/jbc.M608817200.
    1. Kim WY, Nam SJ, Kim S, Kim TM, Heo DS, Kim CW, et al. Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities. Leuk Lymphoma. 2015;56(6):1178–1186. doi: 10.3109/10428194.2014.974048.
    1. Kuo TT, Shih LY, Tsang NM. Nasal NK/T cell lymphoma in Taiwan: a clinicopathologic study of 22 cases, with analysis of histologic subtypes, Epstein-Barr virus LMP-1 gene association, and treatment modalities. Int J Surg Pathol. 2004;12(4):375–387. doi: 10.1177/106689690401200410.
    1. Hong J, Park S, Baek HL, Jung JH, Kang IG, Sym SJ, et al. Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma nasal type. Int J Clin Exp Pathol. 2012;5(9):939–947.
    1. Lin Z, Chen B, Xu X, Wang X, Lin G. Analysis of clinical characteristics of 516 patients with non-Hodgkin’s lymphoma in Shanghai area. Hematology. 2014;19(2):99–106. doi: 10.1179/1607845413Y.0000000097.
    1. Cao M, Wang Q, Lingel A, Zhang L. Nuclear factor κB represses the expression of latent membrane protein 1 in Epstein-Barr virus transformed cells. World J Virol. 2014;3(4):22–29. doi: 10.5501/wjv.v3.i4.22.
    1. Bisig B, de Reyniès A, Bonnet C, Sujobert P, Rickman DS, Marafioti T, et al. CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. Haematologica. 2013;98(8):1250–1258. doi: 10.3324/haematol.2012.081935.
    1. Molavi O, Xiong XB, Douglas D, Kneteman N, Nagata S, Pastan I, et al. Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma. Biomaterials. 2013;34(34):8718–8725. doi: 10.1016/j.biomaterials.2013.07.068.
    1. Cao ZG, Zhou HW, Peng CJ, Liu M, Du Y, Yang QM. A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin. Chin J Cancer. 2013;32(9):520–523. doi: 10.5732/cjc.012.10221.
    1. Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O’Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095–3100. doi: 10.1182/blood-2013-12-542142.
    1. Kim HK, Moon SM, Moon JH, Park JE, Byeon S, et al. Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin. Blood Res. 2015;50(4):254–256. doi: 10.5045/br.2015.50.4.254.
    1. Prince HM. CD30 as a target for the treatment of cutaneous T-Cell lymphoma. J Clin Oncol. 2015;33:3691–3696. doi: 10.1200/JCO.2015.61.9486.
    1. Jagadeesh D. A phase II study of single agent brentuximab vedotin in relapsed/refractory CD30 low (<10%) mature T cell lymphoma (TCL). case comprehensive cancer center. . Accessed 28 Sept 2016.
    1. Tse Eric, Kwong Yok-Lam. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target. Exp Mol Med. 2015;47:e136. doi: 10.1038/emm.2014.102.
    1. Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104(1):243–249. doi: 10.1182/blood-2003-12-4197.
    1. Lo YM. Quantitative analysis of Epstein-Barr virus DNA in plasma and serum: applications to tumor detection and monitoring. Ann NY Acad Sci. 2001;945:68–72. doi: 10.1111/j.1749-6632.2001.tb03865.x.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir